Other
MPA
0
Pipeline Programs↗
47
Active Trials↗
114
Companies Involved↗
MPA is an early-stage landscape with 0 programs across 114 companies. The most active players are Pfizer, Boehringer Ingelheim, GSK.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
673
clinical trials
Completed526 · 78%
Unknown status38 · 6%
Terminated28 · 4%
Recruiting21 · 3%
Not yet recruiting18 · 3%
Withdrawn16 · 2%
Other26 · 4%
Clinical Trials
Trial Activity
673 trials
Monitoring Patients With Repetitive Head Impact With Gamma-glutamylcysteine Supplementation
Recruiting·—·Phase 1·NCT07050173·30 enrolled
The Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV Risk
Recruiting·—·Phase 4·NCT05152888·50 enrolled
Clinical Performance of a Novel Self-cured Resin Composite Compared to a Light-cured Bioactive Resin Composite Restoration in Proximal Cavities of Posterior Teeth
Recruiting·—·Phase 1·NCT07457749·50 enrolled
The Diagnostic Observatory: Combating Diagnostic Wandering and Impasse Within the AnDDI-Rares Network
Recruiting·—·N/A·NCT05448326·1,280 enrolled
Page 1 of 45
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)